|
AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, supporting its potential as a new treatment option. The Cambridge, England-based pharmaceuticals firm said the Serena-6 trial showed that switching to camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor after the emergence of an ESR1 mutation led to a statistically significant and clinically meaningful improvement in progression-free survival, compared with continuing treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The company said the study is the first to use a circulating tumour DNA-guided approach to detect endocrine resistance early and adjust treatment before disease progression. Key secondary endpoints, including time-to-second disease progression and overall survival, remain under evaluation. AstraZeneca said camizestrant worked with all widely approved CDK4/6 inhibitorspalbociclib, ribociclib, and abemaciclibwhile maintaining a safety profile consistent with existing treatments. The company plans to present full results at an upcoming medical meeting and share findings with regulatory authorities. Shares in AstraZeneca were up 1.2% at 12,080.00 pence in London on Wednesday morning. Copyright 2025 Alliance News Ltd. All Rights reserved.
|
